











Nucleus tractus solitarii (NTS) is the recipient of sensory
information from the gastrointestinal (GI) tract relayed
centrally via vagal afferent nerves (Rogers et al. 1999;
reviewed by Gillis et al. 1989; Travagli & Rogers, 2001;
Travagli et al. 2003). The NTS then integrates and transfers
this information to the dorsal motor nucleus of the vagus
(DMV) using, in the main, GABA and glutamate as
neurotransmitters (Travagli et al. 1991; Hornby, 2001).
Subsequently, the DMV provides the final modulated vagal
parasympathetic motor output to the subdiaphragmatic
viscera (reviewed by Travagli & Rogers, 2001; Travagli et
al. 2003).
Neuropeptide Y (NPY) and peptide YY (PYY), both
members of the pancreatic polypeptide family of peptides,
have been shown to act centrally to exert profound, vagally
mediated actions on GI function (Geoghegan et al. 1993;
Chen & Rogers, 1995, 1997; Chen et al. 1996, 1997; Yoneda
et al. 1997; Fujimiya et al. 2000; Fujimiya & Inui, 2000;
Kawakubo et al. 2002; Yang, 2002).
Binding sites with similar affinities for NPY and PYY,
specifically Y1 and Y2 receptors, have been identified
within the dorsal vagal complex (DVC, i.e. the NTS and
DMV) (Leslie et al. 1988; Lynch et al. 1989; Dumont et al.
1990). Furthermore, a putative Y3 receptor that recognizes
NPY but not PYY has been proposed to be present in the
NTS (Grundemar et al. 1991; Glaum et al. 1997; Lee &
Miller, 1998).
The lack of readily available pharmacological tools has
prevented investigation of the effects of Y3 receptor
activation on GI function; however, Y1 and Y2 receptor-
mediated differential effects of NPY and PYY on GI
function have been demonstrated in previous studies. For
example, application of PYY either by intravenous injection
or by microinjection directly into the DVC, has been
shown to inhibit gastric motility, gastric acid secretion and
pancreatic secretion, in addition to increasing intestinal
transit time (Adrian et al. 1985; Buell & Harding, 1989;
Masuda et al. 1994; Chen & Rogers, 1995; Naruse et al.
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2002; Yang, 2002). Such actions were abolished by vagotomy
and were mimicked by selective Y2 receptor agonists
(Chen & Rogers, 1995; Chen et al. 1997). Extracellular
recordings in vivo and in vitro suggested that the principal
actions of PYY were to inhibit cholinergic vagal efferent
outflow to the GI tract via direct action at Y2 receptors
located on DMV neuronal cell bodies, even though the
activation of an inhibitory non-adrenergic, non-cholinergic
pathway has also been postulated (Chen & Rogers, 1997).
When administered in high concentrations, however, PYY
has been shown to activate gastric function (Chen &
Rogers, 1995;Yang et al. 1998).
Similar differences in the GI responses to pancreatic
polypeptides (PPs) have also been noted with NPY. For
example, an increase in GI motility and secretion was seen
following NPY administration (Geoghegan et al. 1993;
Chen et al. 1997; Yoneda et al. 1997). Other studies, however,
have noted a decrease in GI motility and secretion (Matsuda
et al. 1993; Chen et al. 1997; Yang et al. 2000; Ishiguchi et al.
2001). Further investigation revealed that the effects of
NPY on gastric motility depend upon the activity of the GI
tract at the time of application. In fact, under basal
conditions, application of NPY to the DVC causes an
increase in gastric motility; however, if gastric motility is
stimulated, NPY has no additional stimulatory effects,
indeed NPY reduces gastric motility (Chen et al. 1997).
It was suggested that such brainstem-mediated diverse
effects on gastric motility were related to different actions
at Y1 versus Y2 receptors, with activation of Y1 receptors
by NPY causing GI stimulation while activation of Y2
receptors by PYY caused GI inhibition (Chen et al. 1997).
To date, however, the cellular determinants of the actions
of NPY and PYY in the dorsal vagal complex (DVC;
i.e. NTS and DMV) have not been examined.
The aims of this study were: (1) to investigate the effects of
NPY and PYY on the membrane of identified GI-
projecting DMV neurons; (2) to investigate their effects on
excitatory and inhibitory synaptic transmission within
the DVC; and (3) to investigate the receptor subtype(s)
responsible for their effect. Preliminary accounts have
been presented at the 2001 Digestive Disease Week
meeting (Atlanta, GA, USA).
METHODS
Retrograde tracing
Retrograde tracers were applied to discrete GI regions as described
previously (Browning et al. 1999). Briefly, 12-day-old Sprague-
Dawley rat pups of either sex were anaesthetized deeply with a 6 %
solution of halothane with air, in accordance with the University
of Michigan Committee on the Use and Care of Animals.
Anaesthesia was maintained during surgery by placing the head
of the animal in a custom-made chamber through which the
halothane–air mixture was administered. The depth of anaesthesia
was monitored (abolition of the foot pinch withdrawal reflex)
prior to and during surgery. An abdominal laparotomy was
performed and crystals of the retrograde tracer 1,1‚-dioctadecyl-
3,3,3‚,3‚-tetramethylinodcarbocyanine perchlorate (DiI) were
applied to the serosal surface of the major curvature of the gastric
fundus or corpus, to the antrum/pylorus, to the duodenum (to the
antimesenteric surface at the level of the bifurcation of the hepatic
and pancreatico–duodenal junction) or to the caecum (at the level
of the ileo–caecal junction). The dye was embedded in place with
epoxy resin that was allowed to harden before the entire surgical
area was flushed with warmed sterile saline and the wound closed
with 5/0 suture. The animal was allowed to recover for 10–15 days
prior to removal of the brainstem for electrophysiological study.
Electrophysiology
The method of the removal and slicing of the brainstem has been
described already (Travagli et al. 1991; Browning et al. 1999).
Briefly, the rats were anaesthetized deeply with halothane before
being killed by induction of a bilateral pneumothorax. The
brainstem was removed and placed in oxygenated physiological
saline solution at 4 °C. Using a vibratome, six to eight coronal
slices (200 mm thick) containing the DVC were cut. The brain-
stem slices were stored in oxygenated physiological saline at
35 ± 1 °C for at least 90 min prior to use.
A single slice was transferred to the oxygenated perfusion chamber
on the stage of a Nikon E600FN microscope equipped with TRITC
epifluorescence filters. The slice was held in place with a nylon
mesh and maintained at 35 ± 1 °C by continuous perfusion with
warmed Krebs solution. Once a DiI-filled neuron was identified,
its identity was confirmed under bright field illumination using
DIC optics. The brief (< 2 s) periods of illumination used to
identify a DiI-filled neuron do not alter its electrophysiological
properties (Mendelowitz & Kunze, 1991; Browning et al. 1999).
Whole-cell recordings were performed with patch pipettes of
resistance 4–7 MV when filled with potassium gluconate solution
(see below for composition) using a single electrode voltage clamp
amplifier (Axoclamp 1D, Axon Instruments, Union City, CA,
USA). Data were filtered at 2 kHz, digitized via a Digidata 1320
interface and stored on an IBM PC utilizing pCLAMP8 software
(Axon Instruments). Only recordings with a series resistance
(i.e. pipette + access resistance) < 15 MV were used. For a neuron
to be considered acceptable for recording, it had to be stable at the
holding potential, the action potential evoked following injection
of DC had to overshoot and the membrane had to return to
baseline after the after-hyperpolarization. Data analysis was
performed using pCLAMP8 software.
Electrical stimulation
Excitatory postsynaptic currents (EPSCs) were recorded from
neurons that were voltage clamped at _60 mV. Inhibitory
postsynaptic currents (IPSCs) were recorded from neurons that
were voltage clamped at _50 mV and bathed continuously with
Krebs solution containing the non-selective glutamate antagonist
kynurenic acid (1 mM). Bipolar tungsten electrodes (WPI Ltd,
Sarasota, FL, USA) were used to stimulate electrically the NTS.
Pairs of stimuli (0.1–1.0 ms, 10–500 mA) were applied using a
Master 8 stimulator (AMPI, Jerusalem, Israel) every 20 s to evoke
submaximal EPSCs (average 299 ± 10 pA) or submaximal IPSCs
(average 307 ± 32 pA). Note that the variations in EPSC or IPSC
amplitude in any one neuron were ±5 %. The value of each evoked
current was thus taken as the average of at least three traces.
Drug application and statistical analysis
Drugs were applied to the bath via a series of manually operated
valves. Results were compared before and after drug administration,












with each neuron serving as its own control (Student’s paired
t test). When different concentrations of BIBP3226 were tested,
the results were analysed using the group t test. Results are
expressed as means ± S.E.M. with significance defined as P < 0.05.
Cells were classified as responders if perfusion with PPs (100 nM)
induced at least a 10 % variation in the peak amplitude of the
evoked EPSCs or IPSCs. Similarly, neurons were classified as
responders if perfusion with PPs (100 nM) induced a membrane
current larger than 15 pA. Comparisons of responsive vs. non-
responsive neurons in the treatment groups were analysed using
the x2 test. Results are expressed as means ± S.E.M. with significance
defined as P < 0.05.
The concentration–response curves for NPY and PYY (Fig. 1) were
obtained using data from neurons on which at least three different
concentrations of PPs were tested. The responses to perfusion
with 0.3 and 1 mM NPY or PYY did not induce a significant
decrease in the amplitude of the EPSCs. These data were not
included because the small inhibition and the ±5 % variation in
the EPSC amplitude generated unreliable measurements. The
curves were generated using the regression analysis function in the
Statistica software (Statsoft, Tulsa, OK, USA). The concentration
of PPs that produced the half-maximum drug response (EC50) was
estimated using a third order polynomial regression (Pitts et al.
1990).
Drugs and solutions
Krebs solution (mM): 126 NaCl, 25 NaHCO3, 2.5 KCl, 1.2 MgCl,
2.4 CaCl2, 1.2 NaH2PO4 and 11 dextrose, maintained at pH 7.4 by
bubbling with 95 % O2–5 % CO2. Intracellular solution (mM): 128
potassium gluconate; 10 KCl, 0.3 CaCl2, 1 MgCl2, 10 Hepes, 1
EGTA, 2 Na2ATP and 0.25 NaGTP, adjusted to pH 7.35 with
KOH. DiI was purchased from Molecular Probes (Eugene, OR,
USA); NPY, PYY, [Leu31,Pro34]NPY and NPY(3–36), diprotin-A
and yohimbine were purchased from Bachem (King of Prussia,
PA, USA). All other chemicals were purchased from Sigma
Chemical Company (St Louis, MO, USA).
RESULTS
NPY, PYY, [Leu31,Pro34]NPY or NPY(3–36) was applied
to a total of 350 GI-projecting DMV neurons (255
gastric, 95 intestinal); 86 of these neurons were tested with
more than one agonist. The response to pharmacological
treatments did not reveal any qualitative (i.e. percentage of
responsive neurons and type of response) or quantitative
(i.e. amplitude of the response) difference between gastric-
and intestinal-projecting neurons; all the data were
therefore pooled.
Presynaptic effects of PPs – excitatory synaptic
transmission
EPSCs were evoked upon stimulation of the adjacent NTS
and recorded from identified DMV neurons. Perfusion
with NPY and PYY (0.1–300 nM for both) induced a
concentration-dependent inhibition in amplitude of evoked
EPSCs in the majority of DMV neurons (94/145 or 65 % of
neurons for NPY and 80/125 or 64 % of neurons for PYY;
Fig. 1). The remaining neurons were unresponsive to NPY or
PYY. The effects of NPY and PYY were qualitatively and
quantitatively similar: both produced similar maximum
decrease in EPSC amplitude at 100 nM (30 ± 1.7 % reduction
of EPSCs peak amplitude for NPY and 32 ± 1.9 %
reduction for PYY) and had similar estimated IC50 values
(approximately 40 nM).
In neurons in which NPY (100 nM) or PYY (100 nM)
decreased EPSC amplitude, the ratio of the EPSCs evoked
by two identical electrical pulses delivered a few milli-
seconds apart increased from a control value of 0.82 ± 0.04
to 1.07 ± 0.05 (for NPY, P < 0.05; Fig. 2A and B) and from
0.80 ± 0.03 to 0.96 ± 0.04 (for PYY, P < 0.05). Such an
alteration in the paired-pulse ratio is suggestive of a
presynaptic site of action.
The presynaptic site of action of NPY and PYY was further
confirmed by monitoring the input resistance of the DMV
neuron before and during PP application. In 19 neurons in
which NPY (n = 9) or PYY (n = 10) decreased the amplitude
of the EPSCs, the value of the input resistance was 462 ±
59 MV. In the presence of NPY or PYY the input resistance
was 447 ± 69 MV (P > 0.05; Fig. 2C). In these cells,
the EPSC rise time was 1.53 ± 0.11 ms in control and
1.48 ± 0.12 ms following NPY or PYY (P > 0.05). Similarly,
the EPSC decay time was 2.81 ± 0.22 ms in control and
2.84 ± 0.22 ms following NPY or PYY (P > 0.05).
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Figure 1. NPY and PYY induced a
concentration-dependent inhibition in
evoked EPSC amplitude
A, representative traces showing the concentration-
dependent inhibition of the evoked EPSC amplitude
by NPY. Full recovery was achieved between
successive applications of NPY. Each trace is the
average of 3 EPSCs. Holding potential, _60 mV.
B, graphical representation of the concentration-
dependent effects of NPY and PYY expressed as
percentage reduction in EPSC amplitude. Note that
both NPY and PYY induced inhibitions of similar
magnitudes and had similar estimated IC50 values.
(Each data point represents the average of 3–18












The response to NPY or PYY did not show tachyphylaxis.
In fact, repeated superfusions of the preparation with
100 nM NPY or PYY 15 min apart gave similar results
(Fig. 3A). In detail, the first superfusion of NPY decreased
the EPSC amplitude by 24 ± 4.3 % (from 163 ± 26 pA in
control to 122 ± 17 pA in NPY; P < 0.05 vs. control; n = 4)
while the second superfusion of NPY decreased the EPSC
amplitude by 27 ± 5.7 % (from 163 ± 33 pA in control
to 115 ± 19 pA in NPY; P < 0.05 vs. control; P > 0.05 vs.
first application). Similarly, the first superfusion of PYY
decreased the EPSC amplitude by 30 ± 5.1 % (from
219 ± 31 pA in control to 156 ± 33.3 pA in PYY; P < 0.05
vs. control; n = 4) while the second superfusion of PYY
decreased the EPSC amplitude by 31 ± 7.5 % (from
192 ± 20.3 pA in control to 130 ± 14 pA in PYY; P < 0.05
vs. control; P > 0.05 vs. first application).
Y1 and Y2 receptor selective agonists mimicked the
inhibitory effects of NPY and PYY
The Y1 receptor selective agonist [Leu31,Pro34]NPY was
applied to 89 neurons (64 gastric- and 25 intestinal-
projecting) and induced an inhibition in amplitude of
evoked EPSCs in approximately 53 % of the neurons
(55 % gastric- and 48 % intestinal-projecting neurons).
[Leu31,Pro34]NPY (100 nM) induced a 23 ± 1.8 % inhibition
in EPSC amplitude (P < 0.05) that was accompanied by an
increase in the paired-pulse ratio (from 0.72 ± 0.04 to
0.91 ± 0.06; P < 0.05). Such inhibitory effects were
prevented by pretreatment with the Y1 receptor selective
antagonist, BIBP3226 (Rudolf et al. 1994; Jacques et
al. 1995). In four neurons, [Leu31,Pro34]NPY induced a
26 ± 7.4 % inhibition in evoked EPSC amplitude. Following
wash out and 10 min perfusion with 0.1 mM BIBP3226, the
inhibition induced by [Leu31,Pro34]NPY was reduced to
1 ± 2.6 % (P > 0.05 compared with control; P < 0.05
compared with inhibition in the absence of antagonist).
Perfusion with the Y2 receptor selective agonist NPY(3–36)
(100 nM) was applied to 68 neurons (47 gastric- and 21
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Figure 2. NPY and PYY decreased the EPSC amplitude via
actions at presynaptic sites
A, representative traces showing the inhibition in EPSC amplitude
induced by NPY (100 nM) and alteration in the paired-pulse ratio
(the paired-pulse ratio compares the amplitude of the second
current (C2) with that of the first current (C1); EPSCs were evoked
40 ms apart). Each trace is the average of 3 EPSCs. B, the evoked
EPSCs obtained in the presence of NPY (100 nM) were normalised
to the amplitude of the control trace. The changes in the paired
pulse ratio are more visible as a result. C, application of PYY
(100 nM) does not affect the membrane responses to
hyperpolarizing voltage commands between _50 and _60 mV.
Figure 3. The presynaptic inhibitory actions of NPY and
PYY were mimicked by Y1 and Y2 receptor selective
agonists
A1, perfusion with NPY (100 nM) decreased the amplitude of the
evoked EPSCs; A2, following a 10 min washout, NPY perfusion
induced a similar inhibition of the evoked EPSCs. B, representative
traces showing that the Y1 receptor selective agonist
[Leu31,Pro34]NPY (100 nM) inhibited the amplitude of the evoked
EPSCs. Pretreatment with the Y1 receptor selective antagonist
BIBP3226 (0.1 mM) prevented the inhibition induced by
[Leu31,Pro34]NPY. C, in another neuron, EPSCs were evoked as in
A. The Y2 receptor selective agonist NPY(3–36) (100 nM) induced
an inhibition in the amplitude of the evoked EPSCs that was
unaffected by the Y1 receptor selective antagonist BIBP3226













intestinal-projecting DMV neurons) and inhibited evoked
EPSC amplitude in 41 % of neurons (66 % gastric, 48 %
intestinal). The maximum inhibition in EPSC amplitude
induced by NPY(3–36) (100 nM) was 26 ± 2.1 % (P < 0.05)
and was accompanied by an increase in the paired-pulse
ratio (0.87 ± 0.06 to 1.08 ± 0.08, P < 0.05). The presynaptic
inhibitory effects of 100 nM NPY(3–36) were unaffected
by pretreatment with the Y1 antagonist BIBP3226, even
at a concentration (1 mM) that is 10-fold higher than
that required to completely antagonize the effects of
[Leu31,Pro34]NPY. Specifically, in four neurons, NPY(3–36)
induced a 21 ± 6.0 % inhibition in evoked EPSC amplitude.
Following wash out and 10 min perfusion with BIBP3226,
NPY(3–36) induced a 24 ± 11.2 % inhibition (P < 0.05
compared with control; P > 0.05 compared with inhibition
in the absence of antagonist; Fig. 3C).
The Y1 antagonist, BIBP3226, prevented the effects
of NPY but not PYY
BIBP3226 attenuated the ability of NPY, but not PYY, to
inhibit EPSC amplitude. In detail, 100 nM NPY induced a
30 ± 4.5 % inhibition in EPSC amplitude; following wash
out and 10 min pretreatment with 0.1 mM BIBP3226, the
NPY-induced inhibition was attenuated partially to
19 ± 3.3 % (n = 8; P < 0.05). In another set of neurons,
100 nM NPY induced a 20 ± 2.8 % inhibition in EPSC
amplitude; following wash out and 10 min pretreatment
with 1 mM BIBP3226, the NPY-induced inhibition was
antagonized completely to 1 ± 4.1 % (n = 5; P > 0.05 vs.
control; P < 0.05 vs. BIBP3226 0.1 mM; Fig. 3C). In
contrast, even at 1 mM BIBP3226 had no effect on the
inhibition of EPSC amplitude induced by 100 nM PYY. In
detail, PYY perfusion induced a 22 ± 3.1 % inhibition in
EPSC amplitude; in the presence of 1 mM BIBP3226, PYY
induced a 19 ± 3.6 % inhibition (n = 5; P < 0.05 compared
with control; P > 0.05 compared with inhibition in the
absence of BIBP3226).
Both NPY and PYY are subject to enzymatic cleavage by
endogenous diaminopeptidase IV (DAP IV) to form
selective Y2 receptor agonists such as NPY(3–36) and
PYY(3–36) (Grandt et al. 1993; Mentlein et al. 1993). Since
the inhibitory actions of NPY were completely prevented
by the Y1 receptor selective antagonist BIBP3226 (0.1 mM),
one can assume that enzymatic degradation of NPY to
form a Y2 receptor selective agonist does not occur to a
significant degree. The actions of PYY, however, were
unaffected by the Y1 antagonist, even at the higher
concentration (1 mM), raising the possibility that PYY
was cleaved to a Y2 receptor selective agonist. In order
to ascertain whether, under the current experimental
conditions, PYY was prevented from exerting any actions
at presynaptic Y1 receptors because of enzymatic cleavage
to a Y2 receptor selective ligand, we tested whether
BIBP3226 attenuated the inhibitory effects of PYY in the
presence of the DAP IV inhibitor diprotin-A (1 mM). In
detail, in four neurons, PYY induced a 33 ± 4.5 %
inhibition in evoked EPSC amplitude. Following 10 min
superfusion with a combination of diprotin-A and 1 mM
BIBP3226 (which per se had no effect on the EPSC
amplitude), the PYY-induced inhibition was unchanged at
32 ± 5.3 % (P < 0.05 compared with control; P > 0.05
compared with PYY in the absence of peptidase inhibitor
and antagonist).
Interactions of PPs with a adrenoceptors: studies
with agonists
Since many reports have demonstrated that the effects of
NPY are related to noradrenaline (NA) release (Wiley &
Owyang, 1987; Martire & Pistritto, 1992; Khanna et al.
1993; Sawa et al. 1995; Kapoor & Sladek, 2001), we assessed
the effects of pharmacological manipulations of adreno-
ceptors on the inhibition of EPSC amplitude induced by
NPY and PYY.
In six neurons, NPY (100 nM) induced a 26 ± 3.9 %
inhibition in EPSC amplitude (P < 0.05). In those same
neurons, perfusion with the a2 adrenoceptor agonist
UK14,304 (1 mM) induced 22 ± 2.5 % inhibition in EPSC
amplitude (P < 0.05). In the presence of UK14,304,
however, the inhibition induced by NPY was reduced to
12 ± 5.3 % (P < 0.05 compared with control, P < 0.05
compared with the inhibition in the absence of UK14,304).
However, the occlusion of the inhibitory effects of NPY in
the presence of a2 adrenoceptor activation was not due to a
limitation in the maximum possible inhibition in EPSC
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Figure 4. The inhibitory effects of NPY involve the
activation of both Y1 and a2 presynaptic receptors
NPY (100 nM) induced an inhibition in evoked EPSC amplitude
that was antagonized partially by pretreatment with the Y1
receptor selective antagonist BIBP3226 (0.1 mM) but antagonized
completely by a pretreatment with a combination of BIBP3225
(0.1 mM) and yohimbine (10 mM). * P < 0.05 vs. NPY alone;












amplitude; in fact, in three neurons, UK14,304 induced a
47 ± 11.0 % inhibition in EPSC amplitude (P < 0.05).
Addition of methionine enkephalin (1 mM) caused an
additional 35 ± 11.5 % reduction in EPSC amplitude
reducing EPSC amplitude to 18 ± 11.5 % of control
(P < 0.05 compared with inhibition in the absence of
methionine enkephalin, P < 0.05 compared with control),
In contrast, perfusion with UK14,304 did not occlude the
inhibition of EPSC amplitude induced by 100 nM PYY
(29 ± 6.9 and 26 ± 7.4 % in PYY and in PYY + UK14,304,
respectively; n = 6, P > 0.05) or by 100 nM [Leu31,Pro34]NPY
(20 ± 3.5 and 28 ± 4.2 % in [Leu31,Pro34]NPY and in
[Leu31,Pro34]NPY + UK14,304, respectively; n = 5, P > 0.05).
Interactions of PPs with a adrenoceptors: studies
with antagonists
In four neurons, NPY (100 nM) induced a 25 ± 4.4 %
inhibition in EPSC amplitude. Following wash out and
10 min superfusion with the a1 adrenoceptor agonist
phenylephrine (10 mM), which itself had no effect on EPSC
amplitude (98.6 ± 3.4 % of control; P > 0.05), the inhibition
of EPSC amplitude induced by NPY was unchanged at
27.1 ± 1.7 % (P > 0.05 compared with inhibition in the
absence of phenylephrine, P < 0.05 compared with control).
Similarly, in four neurons, PYY (100 nM) induced a
24 ± 4.2 and a 25 ± 1.9 % inhibition in evoked EPSC
amplitude in control and in the presence of phenyl-
ephrine, respectively (P > 0.05 compared with inhibition
in the absence of phenylephrine, P < 0.05 compared with
control; data not shown).
In five neurons, NPY induced a 32 ± 2.9 % inhibition in
EPSC amplitude (P < 0.05) that was reduced to 19 ± 4.5 %
following 10 min pretreatment with the a2 adrenoceptor
antagonist yohimbine (10 mM; P < 0.05 vs. control, P < 0.05
compared with inhibition in the absence of yohimbine;
Fig. 5). In contrast, yohimbine pretreatment did not
antagonize the inhibition induced by 100 nM PYY (29 ±
6.9 and 26 ± 7.4 % in PYY and in PYY + yohimbine,
respectively; n = 6; P < 0.05 vs. control; P > 0.05 compared
with inhibition in the absence of yohimbine; Fig. 5) or by
100 nM [Leu31,Pro34]NPY (27 ± 7.7 and 32 ± 6.3 % in
[Leu31,Pro34]NPY and in [Leu31,Pro34]NPY + yohimbine;
n = 5, P > 0.05).
The Y1 antagonist BIBP3226 and the a2 antagonist
yohimbine prevented the effects of NPY
Pretreatment with 0.1 mM BIBP3226 and 10 mM yohimbine
completely antagonized the ability of NPY to inhibit EPSC
amplitude. In detail, 100 nM NPY induced a 32 ± 7.2 %
inhibition in EPSC amplitude; following wash out and
10 min pretreatment with BIBP3226, the NPY-induced
inhibition was attenuated partially to 23 ± 5.2 % (P < 0.05
vs. NPY alone). Following wash out of NPY and 10 min
perfusion with BIBP and yohimbine, the NPY-induced
inhibition was antagonized almost completely to 5 ± 7.4 %
(n = 3; P > 0.05 vs. control; P < 0.05 vs. BIBP3226 0.1 mM;
Fig. 4).
The effects of NPY were attenuated by pretreatment
with reserpine
The data described above suggest that the inhibitory effects
of NPY might involve the activation of inhibitory
adrenoceptors. To ascertain whether this involves a direct
interaction of NPY with presynaptic adrenoceptors or an
indirect action via the release of NA, recordings were made
from 10 neurons from eight rats which underwent
chemical sympathectomy with reserpine (5 mg kg_1 I.P.) at
48 and 24 h prior to experimentation (Tricklebank et al.
1984). In these neurons, NPY (100 nM) induced a
30 ± 3.2 % inhibition in evoked EPSC amplitude (P < 0.05
vs. control). In the presence of yohimbine (10 mM), the
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Figure 5. The inhibitory effects
of NPY, but not PYY, involve the
evoked release of NA
PYY (100 nM) induced an inhibition
in evoked EPSC amplitude that was
unaffected by pretreatment with thea2 adrenoceptor antagonist
yohimbine (10 mM). Conversely NPY
(100 nM) induced an inhibition of
evoked EPSCs that was partially
prevented by pretreatment with
yohimbine. Following treatment with
reserpine, however, the NPY-induced
inhibition was unaffected by
yohimbine and completely
antagonized by 0.1 mM BIBP3226.












inhibition induced by NPY was 27 ± 2.7 % (n = 6; P < 0.05
vs. control; P > 0.05 compared with NPY in the absence of
yohimbine), i.e. following pretreatment with reserpine,
the ability of yohimbine to partially attenuate the actions
of NPY was ablated (Fig. 5). Furthermore, in the four
remaining neurons from reserpine-treated rats, perfusion
with NPY induced a 29 ± 3.4 % inhibition in evoked EPSC
amplitude (P < 0.05 vs. control). In the presence of 0.1 mM
BIBP3226, the NPY effects were completely antagonized
(i.e. a 0 ± 3.5 % inhibition; Fig. 5).
Responses to multiple peptides
Out of 38 neurons in which the actions of both NPY and
PYY were assessed, both peptides were effective in
reducing the amplitude of evoked EPSCs in 10 neurons. In
a further nine neurons, PYY (but not NPY) inhibited
excitatory synaptic transmission while in the remaining 19
neurons, neither peptide had any effect.
In 28 neurons in which the actions of both the Y1 receptor
selective agonist [Leu31,Pro34]NPY and the Y2 receptor
selective agonist NPY(3–36) (100 nM for both) were
assessed, in eight neurons both peptides inhibited
EPSC amplitude. In three neurons, however, only
[Leu31,Pro34]NPY had any effect while in five neurons, only
NPY(3–36) reduced evoked EPSC amplitude. In the
remaining 12 neurons, neither agonist had any effect.
In 6 of the 10 neurons in which the actions of both NPY
and the Y1 receptor selective agonist [Leu31,Pro34]NPY
(100 nM for both) were assessed, both peptides inhibited
EPSC amplitude. In one neuron, however, only NPY
had any effect. There were no occasions in which
[Leu31,Pro34]NPY but not NPY was effective in decreasing
the amplitude of evoked EPSCs.
In 5 of 10 neurons in which the actions of both PYY and the
Y2 receptor selective agonist NPY(3–36) (100 nM for both)
were assessed, both peptides inhibited EPSC amplitude.
There were no occasions when PYY but not NPY(3–36) or
vice versa, was effective in decreasing the amplitude of
evoked EPSCs. In the remaining five neurons, neither
agonist had any effect. Results are summarized in Table 1.
Presynaptic effects of PPs – inhibitory synaptic
transmission
NPY (100–300 nM) and PYY (100–300 nM) were applied
to 19 neurons. Neither NPY (n = 8) nor PYY (n = 11) had
any effect on evoked IPSC amplitude. In detail, in control
conditions the amplitude of evoked IPSCs was 307 ±
53 pA; in the presence of NPY (100 nM) the IPSCs
amplitude was 311 ± 53 pA (P > 0.05). Similarly, in
control the amplitude of evoked IPSCs was 307 ± 42 pA
compared with 297 ± 39 pA in the presence of PYY
(P > 0.05; Fig. 6).
Postynaptic effects of PPs
The postsynaptic response of NPY and PYY (both at
100 nM) did not differ either qualitatively or quantitatively
in any neuronal type tested. An outward current of
28 ± 2.8 pA was induced by perfusion with NPY or PYY in
26 out of the 150 DMV neurons analysed, while an inward
current of 27 ± 2.7 pA was induced in another 20 DMV
neurons. The remaining 104 neurons either showed no
response or responded with a change in current below the
arbitrarily set limit of acceptance (15 pA). The low
percentage of responsive neurons and the small amplitude
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Figure 6. NPY and PYY did not alter evoked IPSC
amplitude
Neurons were voltage clamped at _50 mV and IPSCs evoked by
electrical stimulation of the NTS. Superfusion with NPY (100 nM;
A) or PYY (100 nM; B) did not have any effect on the amplitude of
evoked IPSCs. Each trace is the average of 3 IPSCs.
Table 1. Response to multiple peptides
[Leu31,Pro34]NPY NPY and PYY and 
NPY and PYY and NPY(3–36) [Leu31,Pro34]NPY NPY (3–36)
Both responsive 10 8 6 5
Neither responsive 19 12 3 5
NPY only 0 — 1 —
PYY only 8 — — 0
[Leu31,Pro34]NPY only — 3 0 —
NPY (3-36) only — 5 — 0












of the postsynaptic currents prevented the pursuit of a
thorough voltage clamp study.
DISCUSSION
Using whole-cell patch clamp recordings from identified
GI-projecting neurons of the rat DMV, we have
demonstrated that the main effect of PPs in the DVC is
to inhibit glutamatergic synaptic transmission between
the NTS and the DMV rather than to alter GABAergic
synaptic transmission or exert a direct effect on the DMV
preganglionic motoneurons themselves. Our pharmaco-
logical evidence suggests that different receptors of the
NPY family are involved. Specifically, activation of Y1, Y2
and another NPY-preferring receptor, possibly the putative
Y3 receptor, inhibits excitatory synaptic transmission
from the NTS to GI-projecting DMV neurons. The effects
of the putative Y3 receptor activation are mediated by
release of NA and its subsequent interaction witha2 adrenoceptors.
Even though the reduction in EPSC amplitude by PPs may
appear relatively modest (~30 %), it should be kept in
mind that relatively small variations in synaptic inputs can
have dramatic effects on the spontaneously active DMV
neurons and on GI motility and secretion. In fact, a similar
reduction in the GABAergic input from NTS to DMV
(Browning & Travagli, 2001) is likely to underlie the
severalfold increase in gastric motility observed upon
administration of 5HT and TRH (McCann et al. 1988; Chi
et al. 1996).
The present study indicates that NPY exerts its presynaptic
inhibitory actions on glutamate currents via interactions
with both the Y1 receptor and with another receptor,
possibly the putative Y3 receptor, which, in turns, triggers
the release of catecholamines with a subsequent a2
adrenoceptor-mediated decrease in EPSCs. Conversely,
PYY appears to reduce EPSC amplitude via a non-Y1 and
a non-Y3 receptor, presumably a Y2 receptor. Such
conclusions are reached through several lines of evidence.
First, the presence of both Y1 and Y2 receptors on nerve
terminals within the DVC was confirmed by the effectiveness
of the receptor selective agonists, [Leu31,Pro34]NPY and
NPY(3–36), respectively, in decreasing the evoked EPSC
amplitude.
Second, the Y1 receptor selective antagonist BIBP3226,
used at a concentration (0.1 mM) that prevented fully the
presynaptic inhibitory actions of the Y1 selective agonist
[Leu31,Pro34]NPY, attenuated, but did not completely
antagonize, the presynaptic inhibitory action of NPY, but
had no effect on the ability of PYY to inhibit evoked EPSC
amplitude. These data, in conjunction with data showing
that all the neurons that are inhibited by [Leu31,Pro34]NPY
are also inhibited by NPY, support the conclusion that a
portion of the inhibitory actions of NPY are mediated by
Y1 receptors.
Conversely, PYY acts at sites other than Y1 and Y3
receptors. Our data show that all the neurons responding
to PYY also respond to NPY(3–36) (Table 1) and that even
at 1 mM, BIBP3226 does not antagonize the inhibitory
effects of PYY, supporting the conclusion that the
receptors that PYY interacts with are neither Y1 nor Y3
receptors but are probably Y2 receptors.
The explanation for such unexpected Y1 and Y2 receptor
selectivity is unclear, because NPY and PYY are supposed
to have similar affinities for both Y1 and Y2 receptors
(Michel et al. 1999). It is unlikely that the lack of effect of
PYY at Y1 receptors is due to degradation of PYY to a
Y2-preferring ligand. In fact, inhibition of the endogenous
enzyme DAP IV, which cleaves the peptide to a
Y2-preferring metabolite (Grandt et al. 1993; Mentlein et
al. 1993), does not uncover any latent Y1 receptor activity
of PYY. On the other hand, it is likely that activation of
another receptor, such as the NPY-preferring Y3 receptor
(Grundemar et al. 1991; Glaum et al. 1997; Lee & Miller,
1998), is involved in the presynaptic inhibitory actions of
NPY since some of its effects had a pharmacological profile
different from that of PYY.
The actions of NPY and PYY also differ in the involvement
of NA in their presynaptic inhibitory effects. While neither
NPY nor PYY effects are occluded by the a1 adrenoceptor
agonist phenylephrine, the inhibitory effects of NPY, but
not PYY, are attenuated partially by a2 adrenoceptor
blockade and are occluded partially by a2 adrenoceptor
activation. The fact that the inhibitory actions of
[Leu31,Pro34]NPY or PYY were not affected by a2 adreno-
ceptor agonists or antagonists suggests that, in addition to
acting at Y1 receptors to inhibit glutamatergic synaptic
transmission directly, NPY also acts at other receptors,
possibly the putative Y3 receptor. Activation of these
receptors, in turn, would induce the release of NA and
activation of presynaptic a2 adrenoceptors that then inhibit
excitatory synaptic transmission (Bertolino et al. 1997).
The DVC receives a dense innervation of noradrenergic
nerve terminals (Rea et al. 1982) principally from
noradrenergic nerve cell bodies within the A2 cell group of
the NTS (Fukuda et al. 1987) and from the locus coeruleus
(Ter Horst et al. 1991). We would like to suggest that the
NPY-mediated NA release and consequent inhibition of
EPSCs is due to the presence of the putative Y3 receptor
only on the terminals of the projections from the locus
coeruleus and/or on catecholaminergic neurons of the
A2 cell group. Our data would suggest that these
noradrenergic terminals, or neurons, express the putative
Y3 receptors only, which would explain the involvement of
NA in the inhibitory actions of NPY but not PYY or
[Leu31,Pro34] NPY. It has been established that these NA-












mediated effects of NPY occur in other areas, both within
the CNS and the periphery (Wiley & Owyang, 1987;
Martire & Pistritto, 1992; Khanna et al. 1993; Sawa et al.
1995; Kapoor & Sladek, 2001).
Interestingly, following reserpine-induced chemical
sympathectomy, pretreatment with yohimbine does not
attenuate the inhibitory actions of NPY, which are, rather,
antagonized completely by pretreatment with 0.1 mM
BIBP3226. These data would suggest that the a2-mediated
responses of NPY are due to release of NA rather that a
direct interaction of NPY with the a2 adrenoceptor itself.
In reserpinized animals the magnitude of EPSC inhibition
induced by NPY is similar to the inhibition obtained in
control rats, which might suggest that following chemical
sympathectomy, there is efficiency of Y1 receptor–effector
coupling and/or that the circuitry has undergone a
receptor rearrangement with an increased expression of
Y1 receptors.
The differences in the mechanisms of inhibition of
excitatory transmission by NPY and PYY may be explained
by considering differences in their functions.
PYY, for example, is a hormone released into the circulation
from enterochromaffin cells following ingestion of a fatty
meal or infusion of lipids into the duodenum (Pappas et al.
1985; Sheikh, 1991; Chen et al. 1997). PYY then acts
centrally to inhibit gastric emptying and motility by a
vagally mediated mechanism, the so-called ileal brake
phenomenon. It is unlikely, however, that in vivo PYY
itself exerts any actions within the DVC, rather, it is more
likely that PYY is cleaved by the circulating endogenous
enzyme, DAP IV, to form selective Y2 receptor agonists
such as PYY(3–36) (Grandt et al. 1993; Mentlein et al.
1993). Previous studies have indeed demonstrated that the
PYY-mediated inhibitory actions on GI motility result
from interactions with Y2 receptors in the brainstem
(Chen & Rogers, 1995, 1997; Chen et al. 1996, 1997). Our
data suggest that PYY interaction with Y2 receptors
induces mainly a decrease in the excitatory transmission
between NTS and DMV.
NPY, in contrast, is contained within neurons of the
dorsomedial NTS and within nerve terminals throughout
the DVC (Harfstrand et al. 1987) and it is released as a
neurotransmitter/neuromodulator. Previous reports have
suggested that the central, vagally mediated effects of NPY
on the GI tract depend upon the basal conditions of the GI
tract at the time of application. Under conditions of
increased levels of GI motility, which would engage an
increased glutamatergic transmission, NPY decreases
motility or gastric acid secretion (Chen et al. 1997). Under
these conditions, neuronal release of NPY was suggested to
activate only Y1 receptors (Chen et al. 1997). The present
study, however, would indicate that NPY activates not
only Y1 but also the putative Y3 receptors, even if Y2
receptors are present. While the vast majority of DMV
neurons are cholinergic (Armstrong et al. 1990), at least
two opposing vagal neuronal pathways exist which can be
differentiated based on the neurochemical phenotype of
the postganglionic enteric neurons they innervate. One
circuit is a cholinergic excitatory pathway, inhibition of
which would cause a decrease in gastric motility and
secretion. The other circuit is a non-adrenergic, non-
cholinergic (NANC) pathway, inhibition of which causes
an increase of gastric tone, most commonly via nitric oxide
release (for reviews see Travagli & Rogers, 2001; Travagli et
al. 2003). Since activation of Y receptors on excitatory
glutamatergic nerve terminals caused a decrease in
glutamate release with a consequent inhibition of the
DMV neuronal output, the overall GI response following
application of PPs in the DVC would be a withdrawal of
the cholinergic tone modulated by brainstem glutamatergic
pathways.
It is interesting to note that only a subpopulation of DMV
neurons appeared to be modulated by PPs. This observation
further support the hypotheses proposed by us and other
groups that there is a high degree of integration within
the DMV that is reflected in discrete pharmacological
properties of the neurons themselves as well as by the
modulation of their synaptic inputs. Unfortunately, the
correlation between these physiological/pharmacological
differences and the function(s) subserved by the vagal
motoneurons is far from being resolved.
In conclusion, we have provided strong evidence
indicating that, under our experimental conditions, the
effects of PPs are due mainly to inhibition of excitatory
synaptic transmission between NTS and DMV. These
effects are due to interactions with different receptors of
the NPY family. NPY directly activates Y1 receptors
located on NTS glutamatergic terminals impinging on
DMV neurons. NPY also activates an NPY-preferring
receptor, possibly the putative Y3 receptor, which releases
NA to decrease the amplitude of EPSCs via a2 adreno-
ceptors. Conversely, PYY inhibits NTS–DMV excitatory
transmission via activation of a non-Y1, non-Y3 receptor,
possibly the Y2 receptor.
REFERENCES
Adrian TE, Savage AP, Sagor GR, Allen JM, Bacarese-Hamilton AJ,
Tatemoto K, Polak JM & Bloom SR (1985). Effect of peptide YY on
gastric, pancreatic, and biliary function in humans.
Gastroenterology 89, 494–499.
Armstrong DM, Manley L, Haycock JW & Hersh LB (1990). Co-
localization of choline acetyltransferase and tyrosine hydroxylase
within neurons of the dorsal motor nucleus of the vagus. J Chem
Neuroanat 3, 133–140.
Bertolino M, Vicini S, Gillis RA & Travagli RA (1997). Presynaptic
alpha-2 adrenoceptors inhibit excitatory synaptic transmission in
rat brain stem. Am J of Physiol 272, G654–661.












Browning KN, Renehan WE & Travagli RA (1999).
Electrophysiological and morphological heterogeneity of rat
dorsal vagal neurons which project to specific areas of the
gastrointestinal tract. J Physiol 517, 521–532.
Browning KN & Travagli RA (2001). The peptide TRH uncovers the
presence of presynaptic 5-HT1A receptors via activation of a
second messenger pathway in the rat dorsal vagal complex.
J Physiol 531, 425–435.
Buell MG & Harding RK (1989). Effects of peptide YY on intestinal
blood flow distribution and motility in the dog. Regul Pept 24,
195–208.
Chen CH & Rogers RC (1995). Central inhibitory action of peptide
YY on gastric motility in rats. Am J Physiol 269, R787–792.
Chen CH & Rogers RC (1997). Peptide YY and the Y2 agonist PYY-
(13–36) inhibit neurons of the dorsal motor nucleus of the vagus.
Am J Physiol 273, R213–218.
Chen CH, Rogers RC & Stephens RL Jr (1996). Intracisternal
injection of peptide YY inhibits gastric emptying in rats. Regul Pept
61, 95–98.
Chen CH, Stephens RL Jr & Rogers RC (1997). PYY and NPY control
of gastric motility via action on Y1 and Y2 receptors in the DVC.
Neurogastroenterol Motil 9, 109–116.
Chi J, Kemerer J & Stephens RL Jr (1996). 5-HT in DVC: disparate
effects on TRH analogue-stimulated gastric acid secretion,
motility, and cytoprotection. Am J Physiol 271, R368–372.
Dumont Y, Fournier A, St Pierre S, Schwartz TW & Quirion R
(1990). Differential distribution of neuropeptide Y1 and Y2
receptors in the rat brain. Eur J Pharmacol 191, 501–503.
Fujimiya M & Inui A (2000). Peptidergic regulation of
gastrointestinal motility in rodents. Peptides 21, 1565–1582.
Fujimiya M, Itoh E, Kihara N, Yamamoto I, Fujimura M & Inui A
(2000). Neuropeptide Y induces fasted pattern of duodenal
motility via Y2 receptors in conscious fed rats. Am J Physiol
Gastrointest Liver Physiol 278, G32–38.
Fukuda A, Minami T, Nabekura J & Oomura Y (1987). The effects of
noradrenaline on neurones in the rat dorsal motor nucleus of the
vagus, in vitro. J Physiol 393, 213–231.
Geoghegan JG, Lawson DC, Cheng CA, Opara E, Taylor IL & Pappas
TN (1993). Intracerebroventricular neuropeptide Y increases
gastric and pancreatic secretion in the dog. Gastroenterology 105,
1069–1077.
Gillis RA, Quest JA, Pagani FD & Norman WP (1989). Control
centers in the central nervous system for regulating
gastrointestinal motility. In Handbook of Physiology, section 6, The
Gastrointestinal System, vol. I, Motility and Circulation, part 2, ed.
Wood JD, pp. 621–683. The American Physiological Society,
Bethesda, MD, USA.
Glaum SR, Miller RJ, Rhim H, Maclean D, Georgic LM, MacKenzie
RG & Grundemar L (1997). Characterization of Y3 receptor-
mediated synaptic inhibition by chimeric neuropeptide Y-peptide
YY peptides in the rat brainstem. Br J Pharmacol 120, 481–487.
Grandt D, Dahms P, Schimiczek M, Eysselein VE, Reeve JR &
Mentlein R (1993). Proteolytic processing by dipeptidyl
aminopeptidase IV generates receptor selectivity for peptide YY.
Med Klin 88, 143–145.
Grundemar L, Wahlestedt C & Reis DJ (1991). Long-lasting
inhibition of the cardiovascular responses to glutamate and the
baroreceptor reflex elicited by neuropeptide Y injected into the
nucleus tractus solitarius of the rat. Neurosci Lett 122, 135–139.
Harfstrand A, Fuxe K, Terenius L & Kalia M (1987). Neuropeptide Y-
immunoreactive perikarya and nerve terminals in the rat medulla
oblongata: relationship to cytoarchitecture and catecholaminergic
cell groups. J Comp Neurol 260, 20–35.
Hornby PJ (2001). Receptors and transmission in the brain-gut axis.
II Excitatory amino acid receptors in the brain-gut axis. Am J
Physiol Gastrointest Liver Physiol 280, G1055–1060.
Ishiguchi T, Amano T, Matsubayashi H, Tada H, Fujita M &
Takahashi T (2001). Centrally administered neuropeptide Y delays
gastric emptying via Y2 receptors in rats. Am J Physiol Regul Integr
Comp Physiol 281, R1522–1530.
Jacques D, Cadieux A, Dumont Y & Quirion R (1995). Apparent
affinity and potency of BIBP3226, a non-peptide neuropeptide Y
receptor antagonist, on purported neuropeptide Y Y1, Y2 and Y3
receptors. Eur J Pharmacol 278, R3–5.
Kapoor JR & Sladek CD (2001). Substance P and NPY differentially
potentiate ATP and adrenergic stimulated vasopressin and
oxytocin release. Am J Physiol Regul Integr Comp Physiol 280,
R69–78.
Kawakubo K, Yang H & Tache Y (2002). Gastric protective effect of
peripheral PYY through PYY preferring receptors in anesthetized
rats. Am J Physiol Gastrointest Liver Physiol 283, G1035–1041.
Khanna S, Sibbald JR & Day TA (1993). Neuropeptide Y modulation
of A1 noradrenergic neuron input to supraoptic vasopressin cells.
Neurosci Lett 161, 60–64.
Lee CC & Miller RJ (1998). Is there really an NPY Y3 receptor? Regul
Pept 75–76, 71–78.
Leslie RA, McDonald TJ & Robertson HA (1988). Autoradiographic
localization of peptide YY and neuropeptide Y binding sites in the
medulla oblongata. Peptides 9, 1071–1076.
Lynch DR, Walker MW, Miller RJ & Snyder SH (1989).
Neuropeptide Y receptor binding sites in rat brain: differential
autoradiographic localizations with 125I-peptide YY and 125I-
neuropeptide Y imply receptor heterogeneity. J Neurosci 9,
2607–2619.
McCann MJ, Hermann GE & Rogers RC (1988). Dorsal medullary
serotonin and gastric motility: enhancement of effects by
thyrotropin-releasing hormone. J Auton Nerv Syst 25, 35–40.
Martire M & Pistritto G (1992). Neuropeptide Y interaction with the
adrenergic transmission line: a study of its effect on alpha-2
adrenergic receptors. Pharmacol Res 25, 203–215.
Masuda M, Tomita H, Okubo K & Miyasaka K (1994). Vagal efferent
nerve-dependent inhibitory action on pancreatic polypeptide and
peptide YY in conscious rats: comparison with somatostatin.
J Auton Nerv Syst 50, 131–138.
Matsuda M, Aono M, Moriga M & Okuma M (1993). Centrally
administered NPY inhibits gastric emptying and intestinal transit
in the rat. Dig Dis Sci 38, 845–850.
Mendelowitz D & Kunze DL (1991). Identification and dissociation
of cardiovascular neurons from the medulla for patch clamp
analysis. Neurosci Lett 132, 217–221.
Mentlein R, Dahms P, Grandt D & Kruger R (1993). Proteolytic
processing of neuropeptide Y and peptide YY by dipeptidyl
peptidase IV. Regul Pept 49, 133–144.
Michel MC, Beck-Sickinger A, Cox H, Doods HN, Herzog H,
Larhammar D, Quirion R, Schwartz T & Westfall TC (1999). XVI
International union of pharmacology reccommendations for the
nomenclature of neuropeptide Y, peptide YY, and pancreatic
polypeptide receptors. Pharmacol Rev 50, 143–150.
Naruse S, Kitagawa M, Ishiguro H & Hayakawa T (2002). Feedback
regulation of pancreatic secretion by peptide YY. Peptides 23,
359–365.
Pappas TN, Tache Y & Debas HT (1985). Opposing central and
peripheral actions of brain-gut peptides: a basis for regulation of
gastric function. Surgery 98, 183–190.












Pitts DK, Kelland MD, Shen RY, Freeman AS & Chiodo LA (1990).
Statistical analysis of dose-response curves in extracellular
electrophysiological studies of single neurons. Synapse 5, 281–293.
Rea MA, Aprison MH & Felten DL (1982). Catecholamines and
serotonin in the caudal medulla of the rat: combined
neurochemical-histofluorescence study. Brain Res Bull 9, 227–236.
Rogers RC, Hermann GE & Travagli RA (1999). Brainstem pathways
responsible for oesophageal control of gastric motility and tone in
the rat. Journal of Physiology 514, 369–383.
Rudolf K, Eberlein W, Engel W, Wieland HA, Willim KD, Entzeroth
M, Wienen W, Beck-Sickinger AG & Doods HN (1994). The first
highly potent and selective non-peptide neuropeptide Y Y1
receptor antagonist: BIBP3226. Eur J Pharmacol 271, R11–13.
Sawa T, Mameya S, Yoshimura M, Itsuno M, Makiyama K, Niwa M
& Taniyama K (1995). Differential mechanism of peptide YY and
neuropeptide Y in inhibiting motility of guinea-pig colon. Eur J
Pharmacol 276, 223–230.
Sheikh SP (1991). Neuropeptide Y and peptide YY: major
modulators of gastrointestinal blood flow and function. Am J
Physiol 261, G701–715.
Ter Horst GJ, Toes GJ & Van Willigen JD (1991). Locus coeruleus
projections to the dorsal motor vagus nucleus in the rat.
Neuroscience 45, 153–160.
Travagli RA, Gillis RA, Rossiter CD & Vicini S (1991). Glutamate and
GABA-mediated synaptic currents in neurons of the rat dorsal
motor nucleus of the vagus. Am J Physiol 260, G531–536.
Travagli RA, Hermann GE, Browning KN & Rogers RC (2003).
Musings on the wanderer: what’s new in our understanding of
vago-vagal reflexes?: III. Activity-dependent plasticity in vago-
vagal reflexes controlling the stomach. Am J Physiol Gastrointest
Liver Physiol 284, G180–187.
Travagli RA & Rogers RC (2001). Receptors and transmission in the
brain-gut axis: potential for novel therapies. V. Fast and slow
extrinsic modulation of dorsal vagal complex circuits. Am J Physiol
Gastrointest Liver Physiol 281, G595–601.
Tricklebank MD, Forler C & Fozard JR (1984). The involvement of
subtypes of the 5-HT1 receptor and of catecholaminergic systems
in the behavioural response to 8-hydroxy-2-(di-n-
propylamino)tetralin in the rat. Eur J Pharmacol 106, 271–282.
Wiley J & Owyang C (1987). Neuropeptide Y inhibits cholinergic
transmission in the isolated guinea pig colon: mediation through
alpha-adrenergic receptors. Proc Natl Acad Sci U S A 84,
2047–2051.
Yang H (2002). Central and peripheral regulation of gastric acid
secretion by peptide YY Peptides 23, 349–358.
Yang H, Kawakubo K, Wong H, Ohning G, Walsh J & Tache Y
(2000). Peripheral PYY inhibits intracisternal TRH-induced
gastric acid secretion by acting in the brain. Am J Physiol
Gastrointest Liver Physiol 279, G575–581.
Yang H, Li WP, Reeve JR, Rivier J & Tache Y (1998). PYY-preferring
receptor in the dorsal vagal complex and its involvement in PYY
stimulation in gastric acid secretion in rats. Br J Pharmacol 123,
1549–1554.
Yoneda M, Yokohama S, Tamori K, Sato Y, Nakamura K & Makino I
(1997). Neuropeptide Y in the dorsal vagal complex stimulates
bicarbonate-dependent bile secretion in rats. Gastroenterology 112,
1673–1680.
Acknowledgements 
This manuscript was supported by NIH grant DK55530. We
would like to thank Drs Moises Hermann and Owyang for critical
comments on earlier versions of the manuscript.
Pancreatic polypeptides in the dorsal vagal complexJ Physiol 549.3 785
